statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen to Participate in Upcoming Investor Conferences

PepGen Inc. (NASDAQ:PEPG  Free Report)  Equities researchers at Wedbush increased their Q1 2024 EPS estimates for shares of PepGen in a research report issued on Wednesday, March...

Research Analysts Issue Forecasts for PepGen Inc.'s Q1 2024 Earnings (NASDAQ:PEPG)

Fmr LLC decreased its stake in PepGen Inc. (NASDAQ:PEPG  Free Report) by 13.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The...

Fmr LLC Lowers Holdings in PepGen Inc. (NASDAQ:PEPG)

- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024...

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...

PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. (NASDAQ:PEPG  Get Free Report) Director Ra Capital Management, L.P. bought 2,557,593 shares of PepGen stock in a transaction dated Friday, February 9th. The stock was acquired at...

PepGen Inc. (NASDAQ:PEPG) Director Acquires $27,212,789.52 in Stock

PepGen announces pricing of $80.1M underwritten offering...

PepGen announces pricing of $80.1M underwritten offering

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

PepGen prices 7.53M shares at $10.635 in underwritten public offering

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Watchers	147
52-Wk Low	$3.72
52-Wk High	$17.51

Volume	77,817.00
52-Wk High	$17.51
52-Wk Low	$3.72

PEPG PepGen Inc

About

Feed

News

Earnings

Fundamentals